サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1577563

菌状息肉症治療薬の世界市場

Mycosis Fungoides Therapeutics

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
菌状息肉症治療薬の世界市場
出版日: 2024年10月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

菌状息肉症治療薬の世界市場は2030年までに5億8,720万米ドルに達する見込み

2023年に4億6,730万米ドルと推定される菌状息肉症治療薬の世界市場は、分析期間2023-2030年にCAGR 3.3%で成長し、2030年には5億8,720万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである低分子医薬品は、CAGR 3.5%を記録し、分析期間終了時には3億7,110万米ドルに達すると予測されます。生物学的製剤セグメントの成長率は、分析期間中CAGR 2.9%と推定されます。

米国市場は1億2,730万米ドルと推定、中国はCAGR6.4％で成長予測

米国の菌状息肉症治療薬市場は、2023年に1億2,730万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR6.4%を牽引し、2030年までに1億2,120万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.5％と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界の菌状息肉症治療薬市場- 主要動向と促進要因まとめ

菌状息肉症とは何か、なぜ効果的な治療管理が重要なのか？

菌状息肉症は皮膚T細胞リンパ腫（CTCL）の最も一般的なタイプであり、主に皮膚を侵すリンパ球のまれな慢性がんです。この疾患は、皮膚に浸潤した悪性T細胞によって特徴付けられ、斑状の発疹、斑点、さらに重症になると腫瘍や全身病変を引き起こします。菌状息肉症は進行性の疾患であり、数年かけて進行し、初期のあまり進行していない段階から、患者のQOLや全生存期間に大きな影響を与える進行した段階へと移行するため、効果的な治療管理が重要です。この疾患は一般的に緩徐な疾患であるが、その多彩な病像とSézary症候群のような侵攻性の亜型に変化する可能性から、皮膚直接治療と全身治療の両方を考慮した包括的な治療アプローチが必要です。この疾患の治療は、数十年間安定した状態を保つ患者もいれば、急速に病勢が進行する患者もおり、その不均一性のために複雑です。そのため、万能の治療法は存在せず、病期、症状の重症度、患者の併存疾患に応じて、各個人に合わせた治療戦略が必要となります。菌状息肉症の複雑性を考慮すると、より効果的で侵襲の少ない治療法の調査は、患者の転帰を改善し、長期的な疾患管理を可能にするために最も重要です。

菌状息肉症の治療における現在の治療アプローチと限界は？

菌状息肉症の治療法は多様であり、病期や病態に応じて局所療法、全身療法、新しい生物学的製剤など様々な治療法があります。初期の菌状息肉症では、コルチコステロイド、局所化学療法剤（例、メクロレタミン）、レチノイド（例、ベキサロテン）などの皮膚指示療法が、限局した皮膚病変の管理と症状の軽減によく用いられます。光線療法、特にナローバンド紫外線B（NB-UVB）およびプソラレン＋紫外線A（PUVA）は、早期患者の寛解達成に有効であることが示されています。さらに進行した症例に対しては、インターフェロン、ボリノスタットのようなヒストン脱アセチル化酵素（HDAC）阻害剤、モガムリズマブのようなモノクローナル抗体などの全身療法が、広範な病変と全身病変をターゲットとして利用されています。このような治療法の選択肢があるにもかかわらず、菌状息肉症は再発しやすく、時間の経過とともに治療抵抗性を示す可能性があるため、依然として治療が困難な疾患です。治療に関連する副作用、長期間の光線療法による二次がんのリスク、進行した病期における限られた有効性など、現在の治療法の限界は、より少ない副作用でより良好なコントロールを提供できる新規治療法の必要性を強調しています。その結果、本疾患の根本的な分子・免疫機構を標的とした新たな治療法の探索が進められており、奏効率の改善、疾患の進行遅延、患者のQOLの向上を目指した新たな治療法が登場しています。

技術的・科学的革新はどのように情勢を変えているのか？

分子生物学と免疫療法における最近の進歩は、菌状息肉症の治療状況を一変させ、より的を絞った効果的な治療への新たな道を提供しています。最も有望な開発分野のひとつは、悪性T細胞を特異的に標的とするように設計された生物学的製剤の使用です。CCR4レセプターを標的とするモノクローナル抗体であるモガムリズマブは、難治性菌状息肉症の患者において、腫瘍の負担を軽減し、症状の緩和をもたらす顕著な有効性を示しています。JAK-STAT経路やPI3K経路など、T細胞の生存や増殖に関与する主要な経路を標的とする他の生物学的製剤や低分子化合物も、様々な臨床開発段階にあります。さらに、がん細胞に対する免疫系の反応を調節するチェックポイント阻害剤も、攻撃的なCTCLの治療薬としての可能性が検討されています。遺伝子や分子のプロファイリングを利用して、個人の疾患特性に合わせた治療を行うプレシジョンメディシンの登場は、治療に革命をもたらす可能性のあるもう一つのブレークスルーです。治療に対する反応を予測する特定のバイオマーカーを同定することは、治療戦略を洗練させ、効果のない薬剤に不必要にさらされることを最小限に抑えるのに役立つと思われます。さらに、高解像度PET/CTスキャンなどの高度な画像診断技術により、疾患のモニタリングが改善され、臨床医が進行の兆候を早期に発見し、それに応じて治療計画を調整できるようになりつつあります。これらの技術革新は、菌状息肉症の治療選択肢を広げるだけでなく、より個別化された患者中心の治療への道を開くものです。

菌状息肉症治療薬市場の成長を促進する要因は？

菌状息肉症治療薬市場の成長は、主に治療技術の進歩、臨床診療の進化、患者層の変化に影響されるいくつかの要因によって牽引されています。主な要因のひとつは、菌状息肉症やその他の皮膚リンパ腫の有病率が増加していることであり、特にこれらの疾患に罹患しやすい高齢者層が増加しています。高齢者人口の増加は患者層を大幅に拡大し、効果的で忍容性の高い治療オプションに対する需要を促進しています。さらに、早期診断への注目が高まり、高度な診断ツールの導入が進んだことで、より多くの患者が早期段階で発見されるようになり、早期段階での治療介入の必要性が高まっています。もう一つの主な要因は研究開発活動の急増であり、複数の製薬会社が進行性菌状息肉症のアンメットニーズに対応するため、新規の生物学的製剤や標的療法に多額の投資を行っています。現在進行中の個別化医療へのシフトは、臨床医や研究者が特定の疾患プロファイルに合致した治療を行おうと努力しているため、市場の成長をさらに後押ししています。また、菌状息肉症のような慢性疾患のモニタリングや管理に遠隔医療やデジタルヘルスプラットフォームの利用が増加していることも、市場拡大に寄与しています。これらの技術は患者の関与を高め、より効果的な長期的疾患管理を可能にするからです。さらに、希少疾病治療薬に対する希少疾病用医薬品の指定や迅速な承認経路など、有利な規制の枠組みが、革新的な治療薬の開発と商業化を後押ししています。これらの要因が相まって、菌状息肉症治療薬市場の将来が形成されつつあり、より広範ながん・皮膚科領域においてダイナミックで急速に進化するセグメントとなっています。

調査対象企業の例（注目の44社）

  • 4SC
  • BioInvent International AB
  • Bristol-Myers Squibb Company
  • Cartherics Pty Ltd.
  • Citius Pharmaceuticals, Inc.
  • CRISPR Therapeutics
  • Helsinn Healthcare SA
  • Innate Pharma SA
  • Kite Pharma, Inc.
  • Kyowa Kirin Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24281

Global Mycosis Fungoides Therapeutics Market to Reach US$587.2 Million by 2030

The global market for Mycosis Fungoides Therapeutics estimated at US$467.3 Million in the year 2023, is expected to reach US$587.2 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2023-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$371.1 Million by the end of the analysis period. Growth in the Biologic Drugs segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$127.3 Million While China is Forecast to Grow at 6.4% CAGR

The Mycosis Fungoides Therapeutics market in the U.S. is estimated at US$127.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$121.2 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Mycosis Fungoides Therapeutics Market - Key Trends and Drivers Summarized

What Is Mycosis Fungoides and Why Is Effective Therapeutic Management Crucial?

Mycosis Fungoides is the most common type of cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer of the lymphocytes that primarily affects the skin. The disease is characterized by malignant T-cells infiltrating the skin, leading to patchy rashes, plaques, and in more severe stages, tumors and systemic involvement. Effective therapeutic management is critical because Mycosis Fungoides is a progressive disease that can evolve over several years, transitioning from early, less aggressive stages to more advanced stages where the disease can significantly impact the patient’s quality of life and overall survival. Although it is typically an indolent condition, its variable presentation and potential to transform into aggressive variants, such as Sézary syndrome, necessitate a comprehensive therapeutic approach that considers both skin-directed and systemic treatments. Managing this disease is complex due to its heterogeneity, with some patients remaining stable for decades while others experience rapid disease progression. As a result, there is no one-size-fits-all treatment, and the therapeutic strategy must be tailored to each individual, depending on the disease stage, severity of symptoms, and patient comorbidities. Given the complexity of Mycosis Fungoides, research into more effective, less invasive therapies continues to be of paramount importance to improve patient outcomes and provide long-term disease control.

What Are the Current Therapeutic Approaches and Limitations in Treating Mycosis Fungoides?

The treatment landscape for Mycosis Fungoides is diverse, encompassing a range of modalities that include topical therapies, systemic drugs, and newer biologics, depending on the stage and presentation of the disease. In early-stage Mycosis Fungoides, skin-directed therapies such as corticosteroids, topical chemotherapy agents (e.g., mechlorethamine), and retinoids (e.g., bexarotene) are commonly used to manage localized skin lesions and alleviate symptoms. Phototherapy, particularly narrowband ultraviolet B (NB-UVB) and psoralen plus ultraviolet A (PUVA), has shown to be effective in achieving remission in early-stage patients. For more advanced cases, systemic therapies, including interferons, histone deacetylase (HDAC) inhibitors like vorinostat, and monoclonal antibodies like mogamulizumab, are utilized to target widespread disease and systemic involvement. Despite the availability of these therapeutic options, Mycosis Fungoides remains a challenging condition to treat due to its relapsing nature and the potential for resistance to therapies over time. The limitations of current therapies, such as treatment-related side effects, risk of secondary cancers with long-term phototherapy, and limited efficacy in advanced stages, underscore the need for novel treatments that can provide better control with fewer adverse effects. As a result, the search for new therapies that target the underlying molecular and immune mechanisms of the disease is ongoing, with emerging treatments aiming to improve response rates, delay disease progression, and enhance patient quality of life.

How Are Technological and Scientific Innovations Changing the Mycosis Fungoides Therapeutics Landscape?

Recent advancements in molecular biology and immunotherapy are transforming the therapeutic landscape for Mycosis Fungoides, providing new avenues for more targeted and effective treatments. One of the most promising areas of development is the use of biologics, which are engineered to specifically target malignant T-cells. Mogamulizumab, a monoclonal antibody targeting the CCR4 receptor, has shown significant efficacy in reducing tumor burden and providing symptom relief in patients with refractory Mycosis Fungoides. Other biologics and small molecules targeting key pathways involved in T-cell survival and proliferation, such as the JAK-STAT and PI3K pathways, are also in various stages of clinical development. Additionally, checkpoint inhibitors, which modulate the immune system’s response to cancer cells, are being explored for their potential to treat aggressive forms of CTCL. The advent of precision medicine, which utilizes genetic and molecular profiling to tailor therapies to the individual’s unique disease characteristics, is another breakthrough that could revolutionize treatment. Identifying specific biomarkers that predict response to therapy could help refine treatment strategies and minimize unnecessary exposure to ineffective drugs. Furthermore, advanced imaging technologies, such as high-definition PET/CT scans, are improving disease monitoring, allowing clinicians to detect early signs of progression and adjust treatment plans accordingly. These innovations are not only expanding the therapeutic options for Mycosis Fungoides but are also paving the way for a more personalized, patient-centered approach to care.

What Factors Are Driving the Growth of the Mycosis Fungoides Therapeutics Market?

The growth in the Mycosis Fungoides therapeutics market is driven by several factors, primarily influenced by advancements in treatment technologies, evolving clinical practices, and changing patient demographics. One of the main drivers is the increasing prevalence of Mycosis Fungoides and other cutaneous lymphomas, particularly in the aging population, which is more susceptible to these conditions. The rise in the elderly population is significantly expanding the patient pool, driving the demand for effective and tolerable treatment options. Additionally, the growing focus on early diagnosis and the increased adoption of sophisticated diagnostic tools are leading to more patients being identified at earlier stages, thereby increasing the need for early-stage therapeutic interventions. Another key factor is the surge in research and development activities, with several pharmaceutical companies investing heavily in novel biologics and targeted therapies to address the unmet needs in advanced Mycosis Fungoides. The ongoing shift towards personalized medicine is further boosting market growth, as clinicians and researchers strive to match treatments with specific disease profiles. The increasing use of telemedicine and digital health platforms for monitoring and managing chronic conditions like Mycosis Fungoides is also contributing to market expansion, as these technologies enhance patient engagement and enable more effective long-term disease management. Furthermore, favorable regulatory frameworks, including orphan drug designations and expedited approval pathways for rare disease therapies, are incentivizing the development and commercialization of innovative therapeutics. Collectively, these factors are shaping the future of the Mycosis Fungoides therapeutics market, making it a dynamic and rapidly evolving segment within the broader oncology and dermatology space.

Select Competitors (Total 44 Featured) -

  • 4SC
  • BioInvent International AB
  • Bristol-Myers Squibb Company
  • Cartherics Pty Ltd.
  • Citius Pharmaceuticals, Inc.
  • CRISPR Therapeutics
  • Helsinn Healthcare SA
  • Innate Pharma SA
  • Kite Pharma, Inc.
  • Kyowa Kirin Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Mycosis Fungoides Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Mycosis Fungoides Drives Demand for Advanced Therapeutic Solutions
    • Here's the Story: How Growing Awareness and Early Diagnosis Expand the Addressable Market for Mycosis Fungoides Treatments
    • Increasing Focus on Targeted Therapies Propels Market Growth for Novel Drug Developments
    • Advancements in Immunotherapy and Monoclonal Antibodies Generate New Opportunities for Mycosis Fungoides Management
    • Here's How Personalized Medicine Approaches Strengthen the Business Case for Patient-Specific Treatment Protocols
    • Rising Adoption of Combination Therapies Spurs Demand for Multifaceted Treatment Regimens
    • Growing Focus on Minimally Invasive Treatment Options Drives Adoption of Topical and Skin-Directed Therapies
    • Growing Demand for Non-Chemotherapeutic Options Spurs Innovation in Biologic and Immune-Based Therapies
    • Rising Healthcare Expenditure in Emerging Markets Expands Market Scope for Mycosis Fungoides Therapeutics
    • Increasing Use of Digital Health Platforms Transforms Market Dynamics through Enhanced Patient Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mycosis Fungoides Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Small Molecule Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: India 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION